Topiramate for the Prophylactic Treatment of Cyclic Vomiting Syndrome in Children

Vomiting Clinical Trial

Official title:

Topiramate for the Prophylactic Treatment of Cyclic Vomiting Syndrome in Children

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00286988
• Other study ID #: TOPMAT-EME-4001
• Status: Terminated
• Phase: Phase 4
• First received: February 1, 2006
• Last updated: January 5, 2011
• Start date: March 2006
• Est. completion date: June 2007

Study information

• Verified date: April 2007
• Source: Monarch Medical Research
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the effectiveness, tolerability and safety of oral topiramate for the preventative management of Cyclic Vomiting Syndrome. It is believed that topiramate will decrease the frequency, duration and severity of attacks experienced by children and adolescents with Cyclic Vomiting Syndrome.

Description:

There is very little controlled data on the preventative treatment for Cyclic Vomiting Syndrome. The existing evidence consists of small, retrospective clinical series that evaluate symptomatic responses to five medications including cyproheptadine, propranolol, amitriptyline, phenobarbital and pizotifen (n >10). These published data consist of uncontrolled or retrospective reports. In addition, varying inclusion criteria and outcomes (i.e. obtained by family recall) were used in these studies limiting the basis upon which to compare relative effectiveness.

During the prospective baseline period, the subject will maintain cyclical vomiting records in which all headache occurrences will be recorded and characterized. (Cyclical vomiting records will be maintained throughout the study). The purpose of this study is to assess the effectiveness, tolerability and safety of oral topiramate for the preventative management of Cyclic Vomiting Syndrome using a prospective design, established diagnostic criteria (ICHD 2004), and defined, objective primary and secondary endpoints.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 12
• Est. completion date: June 2007
• Est. primary completion date: May 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 4 Years to 12 Years

Eligibility

Inclusion Criteria:

• Meet the2004 ICHD Criteria for Cyclical Vomiting.

• 1 vomiting attack lasting > 24 hours duration for 3 consecutive months

• 4-12 years of age.

• If female, subjects must:

1. be premenarchal or otherwise incapable of pregnancy, or

2. have practiced one of the following methods of contraception for at least one month prior to study entry: hormonal contraceptives, spermicide and barrier, intrauterine device, partner sterility, or

3. be practicing abstinence and agree to continue abstinence or to use an acceptable method of contraception (as listed above) should sexual activity commence.

• Able to take oral medication in tablet form or sprinkle form

• Subjects or their guardians must be willing and able to: a) read and comprehend written instructions, b) complete the assessment forms, c) return for regular visits, and d) adhere to medication regimens.

• Subjects (or their legally acceptable representative) must have signed an informed consent document

Exclusion Criteria

• Have taken topiramate within 14 days prior to the start of the prospective baseline period.

• Have taken certain medications for cyclical vomiting prophylaxis

• Have progressive neurological disorder or a structural disorder of the brain from birth, trauma or past infection.

• Subjects who have taken any medications for migraine prophylaxis, within 2 weeks of the start of the prospective baseline period.

• Subjects starting non-pharmacologic prophylactic approaches (e.g., acupuncture, biofeedback, chiropractic methods) within 1 month prior to Visit 1.

• Require continuing treatment with anticonvulsant therapy for a non-migraine condition.

• Significant major psychiatric disorder (e.g., major depression) or subjects receiving anti-psychotic medication.

• History of attempted suicide or suicidal tendencies.

• History of substance abuse.

• Pregnant or lactating females.

• Have clinically unstable neurological, cardiovascular, gastrointestinal, musculoskeletal, pulmonary or other disease.

• Have any disease or condition that could compromise the function of those body systems that could result in altered absorption, excess accumulation, or impaired metabolism or excretion of the test medications (e.g., abnormal renal and/or hepatic function).

• Have active liver disease.

• Have received an investigational drug or used an investigational device within 30 days of study entry.

• Employees of the investigator, study center, or sponsor (i.e., principal investigator, sub-investigator(s), study coordinators, other study staff, employees, or contractors of each), with direct involvement in the proposed study or other studies under the direction of that investigator, study center or sponsor, as well as family members of the employees or the investigator.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Vomiting

Intervention

Drug:
• Topiramate

Locations

Country	Name	City	State
United States	Monarch Medical Research - Child and Adolescent Neurology	Norfolk	Virginia

Sponsors (2)

Lead Sponsor	Collaborator
Monarch Medical Research	Ortho-McNeil Neurologics, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (2)

Abu-Arafeh I, Russell G. Prevalence and clinical features of abdominal migraine compared with those of migraine headache. Arch Dis Child. 1995 May;72(5):413-7. — View Citation

CULLEN KJ, MA CDONALD WB. The periodic syndrome: its nature and prevalence. Med J Aust. 1963 Aug 3;50(2):167-73. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reduction of cycle frequency as measured by number of days between cycles.
Secondary	Decreased duration of attacks (measured in hours)
Secondary	Decreased intensity of attacks (0-4 point scale; none, mild, moderate, severe, excruciating)
Secondary	Decreased associated symptoms (0-4 point scales; none, mild, moderate, severe, excruciating)
Secondary	Nausea
Secondary	Vomiting
Secondary	Headache
Secondary	Abdominal pain
Secondary	Decreased disability
Secondary	PedMidas
Secondary	Missed school (days per attack)
Secondary	Missed work (parent(s)) (days per attack)
Secondary	Decreased use of acute therapies (e.g. anti-emetics)
Secondary	Decreased emergency department visits.

External Links

•   Click here for more information on Cyclic Vomiting Syndrome